We have identified a tissue-kallikrein-binding protein in human serum and in the serum-free culture media from human lung fibroblasts 
INTRODUCTION
Tissue kallikreins (EC 3.4.21.35 ) are now being located in new tissue sites, including the brain, pituitary gland, pineal body and the vascular wall (Chao et al., , 1986a Simson et al., 1985; Nolly et al., 1985) . We have shown that kallikrein-synthetic rate, mRNA concentrations and the quantities of active or prokallikrein can be altered by dietary manoeuvres or hormones Miller et al., 1984; Ando et al., 1985; Gerald et al., 1986; Chao et al., 1986a (Vahtera & Hamberg, 1976; Sakamoto & Nishikaze, 1980) . We and others have found that purified and 1251-labelled tissue kallikreins or unlabelled enzyme appear to be complexed to form some higher-Mr entities when they were added to human or rodent serum (Rabito et al., 1980; Lawton et al., 1981; Shimamoto et al., 1984) .
A new group of proteinase inhibitors named protease nexins have been found in the serum-free conditioned media of a variety of transformed or malignant cell lines (Baker et al., 1980; Eaton & Baker, 1983; Scott et al., 1985) . Protease nexins formed SDS-stable complexes with thrombin and several other serine proteinases (Baker et al., 1980; Scott & Baker, 1983; Scott et al., 1985) . These findings prompted us to search for a ' nexin-like' tissue-kallikrein-binding protein. In the present paper we describe a new specific tissue-kallikreinbinding protein in human serum and in conditioned culture media from human lung fibroblasts (WI-38) and rodent neuroblastoma x glioma hybrids (NG 108 ). An endogenous tissue-kallikrein-binding protein complex was also identified.
EXPERIMENTAL Purification and agarose-immobilization of kallikreins
Human and rat urinary kallikreins were purified to homogeneity, and antisera were generated in rabbits or sheep (Chao & Margolius, 1979; Shimamoto et al., 1980) . Human urinary kallikrein (2 mg/ml in 0.1 MMops/NaOH buffer, pH 7.3) was mixed with 25 ml of Affi-Gel 15 that had been prewashed with cold distilled water on a sintered-glass filter. Incubation was continued with gentle shaking for 4 h at room temperature and then for 16 h at 4 'C. . The kallikrein-agarose § To whom correspondence and reprint requests should be addressed.
Vol. 239 325 columns were then equilibrated with 0.1 M-NaCI/0.01 Msodium phosphate buffer, pH 7.0. Purified kallikreins were labelled with 1251 by using the lactoperoxidase method as described previously (Shimamoto et al., 1980) . Rat urinary esterase A and rat tonin were purified as described previously (Chao, 1983; Demassieux et al., 1976) . Polyacrylamide-gel electrophoresis SDS/polyacrylamide-gel electrophoresis was performed under denaturing conditions in a 7.5-15% linear-gradient gel . The gels were stained with 0.25% Coomassie Brilliant Blue in 9% (v/v) acetic acid/45 % (v/v) methanol and destained in 9% acetic acid/45% methanol. Slab gels were dried and prepared for autoradiography at -70°C for 24 h. Western-blot analyses Kallikrein and kallikrein-kallikrein-binding protein complexes were detected by autoradiography with 1251-Protein A binding as described previously . Electrophoresis was performed in a 7.5-17.5% -linear-gradient polyacrylamide gel containing 0.1 % SDS.
The proteins were-then electrophoretically transferred to nitrocellulose as described by Burnette (1981) . Electrophoretic transfer was performed at 30V for 18 h at 4 'C. The unstained blots were soaked for 1 h at 40 'C in 0.02 M-Tris/HCl buffer, pH 7.4, containing 0.10 M-NaCl and 5% (w/v) 
2-mercaptoethanol and 2.5% (w/v) SDS] was then added and the samples were boiled for 5 min. Portions (0.05-0.1 ml) were run on a 7.5-15% -gradient acrylamide gel containing 0.1% SDS as described previously (Chao, 1983) .
Kallikrein-agarose affinity chromatography
Human or rat sera were diluted 1: 3 in 0.2 MNaCl/0.01 M-sodium phosphate buffer, pH 7.0 and applied to human or rat kallikrein-Affi-gel 15 columns (1.5 cm x 15 cm) equilibrated with the same buffer. Kallikrein-kallikrein-binding protein complexes were eluted with 0.1 M-acetic acid. The eluted fractions were adjusted to pH 7.0 with 1 M-NaOH. The protein concentration of each fraction was measured by the absorbance at 280 nm.
Materials
Purified bovine low-Mr kininogen was a gift from Dr. buffer, pH 7.0, was added to the control (lanes 1, 5 and 8), 2 M-hydroxylamine, pH 7.4 (lanes 2, 6 and 9), or 20 mM-NaOH (lanes 3, 7 and 10) and incubated for 60 min at 37 'C. The samples were then desalted by centrifugation on Sephadex G-25 columns, boiled in extraction buffer and electrophoresed on a 7.5-15% linear-gradient polyacrylamide gel as described in the legend to Fig. 1 Tissue kallikrein-kallikrein-binding protein complexes were not dissociated by 1 M-hydroxylamine and only slightly dissociated by 10 mM-NaOH (Fig. 2) . This Figure shows that a purified rat tissue kallikrein also forms complexes of similar size in human serum that are relatively resistant to both hydroxylamine and alkali treatment. In addition, two higher-M, rat kallikreincontaining bands are seen in rat serum (Fig. 2, lanes 1-3) . Human tissue kallikrein also forms a 92000-Mr and two higher-Mr SDS-stable complexes with binding protein (s) in rat serum (results not shown). These may represent polymeric forms of the rat binding proteins or multiple binding proteins encoded by different genes. Fig. 3 illustrates competition for human serum kallikreinbinding protein between 1251-labelled human tissue kallikrein and unlabelled kallikreins and other human proteinases and proteins. As expected, unlabelled human tissue kallikrein competes with the labelled enzyme whereas human plasma kallikrein, urokinase, thrombin and collagenase have no effect on complex-formation. Neither low-Mr kininogen substrates of bovine or human origin nor ac-antitrypsin affect complex-formation.
Interestingly, rat urinary kallikrein and a kallikreinrelated kininogenase, rat urinary esterase A, but not rat tonin, also compete with the labelled human tissue kallikrein. Finally, heparin competes in the binding assays (Fig. 3, lane 9) . Heparin in a range of concentrations (heparin/kallikrein ratio 10, 100 and 1000, w/w) has no inhibitory effect on the esterolytic or kininogenase activity of the enzyme (results not shown). Therefore heparin appears to prevent complex-formation by binding to the kallikrein-binding protein in human An endogenous kallikrein-kallikrein-binding protein complex was isolated from human serum by a human tissue kallikrein-agarose affinity column. The endogenous -92000 Mr complex was recognized specifically by an affinity-purified anti-(human kallikrein) antibody (Fig. 6a) and not recognized by an anti-a1-antitrypsin serum in Western-blot analyses (Fig. 6b) . Differentiation of kallikrein-binding protein from a1-antitrypsin and other proteinase inhibitors Although human a1-antitrypsin did not show competition with labelled kallikrein for the binding protein (Fig.  3b) and the endogenous kallikrein-kallikrein-binding protein complex was not recognized by an anti-alantitrypsin serum (Fig. 6b) , further studies were carried out to distinguish between a1-antitrypsin and the kallikrein-binding protein. After human urinary kallikrein was incubated with human serum and immunoprecipitated by an anti-(tissue kallikrein) serum (Shimamoto et al., 1980) , immunoprecipitates were separated and analysed by Western blotting with affinity-purified anti-(human urinary kallikrein) antibody (Fig. 7a) or anti-al-antitrypsin serum (Fig. 7b) . The (Fig. 7b) . The results show that tissue kallikrein can form an immunoprecipitable complex with serum az-antitrypsin, but that the complex is dissociable by the SDS treatment at 100°C, hence the single 54000Mr band in Fig. 7(b) . In contrast, the immunoprecipitated kallikrein-kallikrein-binding protein complex is not affected by this treatment (Fig. 7a) . The binding of human tissue kallikrein to several well-characterized human plasma proteinase inhibitors is shown in Table 1 . 1251-kallikrein was incubated with human serum and any complexes formed were subject to immunoprecipitation by antisera to kallikrein and the other proteins. Some kallikrein immunoprecipitation was detected with antiserum to a1-antitrypsin, but minimal kallikrein was detected in the initial or washed immunoprecipitates produced by the antisera to a2-macroglobulin, inter-a-trypsin inhibitor, kininogens, C1-inactivator and antithrombin III. Finally, no significant difference in tissue kallikrein-kallikrein-binding protein complex-formation, measured by quantitative densitometry, could be found between normal subjects or patients with ac-antitrypsin deficiency. (Geiger et al., 1981) .
Tissue kallikrein and the binding protein form a SDS-stable complex with an apparent Mr of 92000 on SDS/polyacrylamide-gel electrophoresis. From this estimated Mr and that of tissue kallikreins (Mr approx. 38000-40000), an Mr of about 52000-54000 would be expected for the binding protein. However, it is also possible that a peptide fragment is released from the kallikrein-binding protein during complex-formation, as has been observed for thrombin-protease nexin interaction (Scott & Baker, 1983 (Fig. 3b) , but enhances binding between thrombin and protease nexin or between thrombin and antithrombin III (Baker et al., 1980; Scott & Baker, 1983 (Baker et al., 1980; Scott & Baker, 1983 (Fig. 7b) . In contrast, the -92000-Mr kallikrein-kallikrein-binding protein complex from the same immunoprecipitates cannot be recognized by ac-antitrypsin antiserum (Fig.  7b) . Although the Mr of az-antitrypsin is similar to that estimated for kallikrein-binding protein (approx. 52000-54000), these results showed that the kallikreinaz-antitrypsin complex is SDS-unstable whereas the kallikrein-kallikrein-binding protein complex is SDSstable. It is also notable that the binding ofac-antitrypsin to tissue kallikrein could only be detected after several hours of incubation. Finally, the results of the competition studies (Fig. 3b) showed that excess a,-antitrypsin did not diminish the formation of the kallikrein-binding protein complexes. Collectively, the data indicate that kallikrein-binding protein is a new tissue-kallikrein-binding protein, distinct from any described previously.
When rat or human tissue kallikreins were first inhibited by incorporating the active-site-labelling reagents phenylmethanesulphonyl fluoride and D-Phe-D-Phe-L-Arg-CH2C1, the active-site-blocked enzymes did not form complexes with the kallikrein-binding protein.
These findings suggest the possibility that the active-site centre of tissue kallikrein may be involved in the complex-formation. Confusing this suggestion are the data in Fig. 2 , which show that low-Mr kininogen does not interfere with binding protein-enzyme interaction. This result might mean that active-site blockade affects the ability of enzyme to interact with binding protein at some auxiliary binding site(s). The nature of the kallikrein-kallikrein-binding protein interaction awaits studies dependent upon the prior purification of the protein.
There is a lack of species specificity for the kallikrein-binding proteins. 1251-labelled human tissue kallikrein forms SDS-stable complexes with binding protein(s) present in human and rat serum. Similarly, 1251-labelled rat tissue kallikrein not only formed an 92000-Mr complex with rat serum, but also formed a similar complex with human serum (Fig. 2, lanes 1-7) .
Several SDS-stable higher-Mr protein bands were also formed between rat tissue kallikreins and rat serum in addition to the -92000-Mr complex (Fig. 2, lanes 1-3) . These bands may represent polymeric forms or other binding proteins. Furthermore, rat tissue kallikrein (Chao & Margolius, 1979) and rat arginine esterase A (Chao, 1983) , a tissue-kallikrein-related kininogenase, were able to compete with human tissue kallikrein in binding to human serum kallikrein-binding protein (Fig.  3a) .
The present study also demonstrates an endogenous -92000-Mr kallikrein-kallikrein-binding protein complex in human serum (Fig. 6) . Such a complex is also present in rat serum (results not shown). The finding that kallikrein-kallikrein-binding protein complex could be isolated by chromatography on kallikrein-agarose affinity column(s) suggests that the covalent complex might have additional non-covalent binding sites. Circulating autoantibodies to kallikrein have also been isolated with the same affinity column , and perhaps they are responsible for the non-covalent binding of the complex with the kallikrein-agarose affinity column.
In other studies, we have found an 92000-M, protein in rat urine and kidney that could be recognized by a specific monoclonal antibody to rat tissue kallikrein Chao et al., 1986b) . Cell-free translation studies directed by brain, salivary, pancreatic and kidney mRNAs have shown that the Mr values of rat tissue preprokallikreins vary from 30000 to 43 000 (Chao et al., 1986b) . Therefore the 92000 Mr renal immunoreactive material Chao et al., 1986b) 
